Clinical Trials
Bicycle Therapeutics Gears Up for Future Milestones with $555 Million Capital Infusion
Bicycle Therapeutics, funding, catalysts, biotechnology, drug development, clinical trials, investors, capital infusion, milestones.
Crinetics’s Atumelnant Shows Promising Early Results in Congenital Adrenal Hyperplasia Treatment
Crinetics, Atumelnant, congenital adrenal hyperplasia, early data, treatment, clinical trial, cortisol, androgens, ACTH, adrenal glands.
Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial
Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation
Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data
J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.
AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China
AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.
GSK’s Novel Long-Acting Asthma Treatment Shows Promising Results in Phase 3 Trials
GSK, asthma treatment, Phase 3 studies, long-acting, clinical trials, efficacy, safety, respiratory disease
Tezspire Clinical Trials by AstraZeneca and Amgen: Empowering Patient Choice in COPD Treatment
Tezspire, AstraZeneca, Amgen, clinical trials, COPD, patient choice, pivotal studies, treatment.
Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment
Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.
FDA Revokes Accelerated Approval of Helsinn’s Cancer Drug at Company’s Request
FDA, Helsinn, accelerated approval, cancer drug, company request, drug withdrawal, regulatory decision, clinical trials, patient safety.
FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer
FDA, Elevar Therapeutics, Hengrui Pharmaceuticals, liver cancer, combination therapy, rejection, clinical trials.